IL-6 has been shown to have a negative role in immunotherapy. It has been reported that increased levels of IL-6 induce the production of myeloid-derived suppressor cells (MDSCs), which promote an immunosuppressive TME. Studies have shown that combining anti-IL6 with ICI treatment, such as anti-PD-1 immunotherapy, fosters increased anti-tumor activity and improved prognosis [44]. Here, IL6 is linked to neoplasm.